Ralph A. Loren

Overview

Ralph Loren has practiced in all phases of intellectual property for over 35 years. His practice is primarily in litigation and deal work with an emphasis on licensing and due diligence. He has many years of patent prosecution experience, primarily in the life sciences and computer fields. He has litigated numerous patent infringement actions in diverse fields including biotechnology, chemical analyzers, computers, electronic equipment and mechanical devices. He has been involved in a number of interferences in the biotechnology and chemical/mechanical field. He has also litigated numerous trademark and copyright matters. His deal experience ranges from M&A and licensing in the pharma space to licensing and due diligence in the software field.

Ralph Loren has practiced in all phases of intellectual property for over 35 years. His practice is primarily in litigation and deal work with an emphasis on licensing and due diligence. He has many years of patent prosecution experience, primarily in the life sciences and computer fields. He has litigated numerous patent infringement actions in diverse fields including biotechnology, chemical analyzers, computers, electronic equipment and mechanical devices. He has been involved in a number of interferences in the biotechnology and chemical/mechanical field. He has also litigated numerous trademark and copyright matters. His deal experience ranges from M&A and licensing in the pharma space to licensing and due diligence in the software field.

Ralph lectures around the country on a variety of patent, licensing and litigation topics, including arbitration issues. He was a part-time professor at Boston University School of Law, where he taught patent law. He was also the author of a chapter entitled “Alternative Dispute Resolution” in the multi-volume Mathew Bender series, “Intellectual Property Counseling and Litigation.” He is listed as one of the leading Intellectual Property Attorneys in Massachusetts in Chambers USA and has been included in the Massachusetts Super Lawyers listing, a Thomson Reuters publication, numerous times. Ralph is also rated AV Preeminent by Martindale-Hubbell.

Showing Results for

Notable Matters

A Locke Lord team comprised of Douglas Gray (Providence), Ralph Loren (Boston) and Baker Coon(Providence) represented Juvenescence Limited, a leading drug development company based in the British Virgin Islands, focused on the development of therapies to increase human longevity, in connection with the launch of its latest joint venture project, FoxBio Inc.

A Locke Lord team led by Eugene McDermott, Douglas Gray and Baker Coon (all of Providence), represented Juvenescence Limited, a leading drug development company based in the British Virgin Islands, focused on the development of therapies to increase human longevity, in its purchase of 14.4 million shares of AgeX Therapeutics, Inc. for $43.2 million, from its affiliate BioTime, Inc. (NYSE American: BTX).

A Locke Lord team represented Biohaven Pharmaceutical Holding Company Ltd. in its completion of an oversubscribed $80 million private financing, announced on Nov. 1, 2016. According to the Biohaven press release, this financing will be used to advance the company’s late stage clinical pipeline and advance new therapies into clinical trials.

In July 2013, an Edwards Wildman deal team led by Andrew Hughes and Paul Mahoney of our Providence office represented clients Nautic Partners, a private equity firm with more than $2.5 billion of capital under management, and Superior Vision, a Nautic Partners portfolio company based in California, in Superior Vision’s execution of a merger agreement providing for the acquisition of Block Vision, a Maryland-based national provider of vision insurance coverage.

Our Intellectual Property lawyers advised Euroscreen, S.A. in the license of technology and compounds to Ortho-McNeil-Janssen Pharmaceuticals,Inc. Euroscreen is a private Belgian, preclinical-stage company that engages in drug discovery and development of small molecule drugs for unmet medical needs including inflammation, metabolism and sex hormone modulation.

Disclaimer

Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.